A Randomized, Double-blind, Active Controlled, Parallel, Multicenter, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of NVP-1203 in Patients With Acute Low Back Pain
Latest Information Update: 08 Apr 2022
At a glance
- Drugs Aceclofenac/eperisone (Primary)
- Indications Back pain
- Focus Registrational; Therapeutic Use
- Sponsors Navipharm
Most Recent Events
- 03 Jun 2021 Status changed from recruiting to completed.
- 01 Mar 2021 Planned End Date changed from 15 Jan 2021 to 30 Jun 2021.
- 01 Mar 2021 Planned primary completion date changed from 31 Dec 2020 to 15 Jun 2021.